ProCE Banner Activity

Beyond Chemotherapy: Checkpoint Inhibitors Are Changing My Approach to Bladder Cancer

Clinical Thought
The evolution of immune checkpoint inhibitors for advanced bladder cancer may eventually replace chemotherapy. Read my thoughts on these new agents and how I use them in the clinic.

Released: December 14, 2017

Expiration: December 13, 2018

No longer available for credit.

Share

Faculty

Matthew Galsky

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Matthew Galsky, MD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Inovio, Merck, and Pfizer.